The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: A double‐blind, randomized, placebo‐controlled trial
Open accessAbstract
Objective: To evaluate whether treatment with prasterone (dehydroepiandrosterone [DHEA]) would allow the dosage of prednisone (or an equivalent corticosteroid) to be reduced to ≤7.5 mg/day for 2 months or longer while maintaining stable or reduced disease activity in steroid‐dependent women with systemic lupus erythematosus (SLE). Methods: In a double‐blind, randomized trial, 191 female SLE patients receiving prednisone (10–30 mg/day) were treated daily with either placebo, 100 mg of oral prasterone (an adrenal androgen), or 200 mg of oral prasterone for 7–9‐months. At monthly intervals, corticosteroid dosages were reduced by algorithm in patients whose SLE Disease Activity Index (SLEDAI) score was stable or improved. Patients for whom a sustained reduction in the dosage of prednisone (≤7.5 mg/day) was achieved for at least the last 2 months of the 7–9‐month treatment period were classified as responders. Results: Response rates were 41% in the placebo group, 44% in the 100‐mg prasterone group, and 55% in the 200‐mg group (P = 0.110, 200 mg versus placebo). Among the 137 subjects (45 in the placebo group, 47 in the 100‐mg group, and 45 in the 200‐mg group) who had active disease at baseline (defined as SLEDAI score >2), 29%, 38%, and 51%, respectively, were responders (P = 0.031 for 200 mg prasterone versus placebo). Acne was the most common adverse event but was generally mild. Clinical and laboratory changes primarily reflected androgenic effects of prasterone. Conclusion: Among women with lupus disease activity, reducing the dosage of prednisone to ≤7.5 mg/day for a sustained period of time while maintaining stabilization or a reduction of disease activity was possible in a significantly greater proportion of patients treated with oral prasterone, 200 mg once daily, compared with patients treated with placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
DHEA and peripheral androgen and estrogen formation: intracrinology
LABRIE, F., BÉLANGER, A., SIMARD, J., LUU‐THE, V., & LABRIE, C. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb17369.x · Cited by 280
Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells.
Suzuki, T., Suzuki, N., Daynes, R. A., & Engleman, E. G. (1991) · Clinical Immunology and Immunopathology · doi:10.1016/s0090-1229(05)80024-8 · Cited by 277
Dehydroepiandrosterone in systemic lupus erythematosus
Van Vollenhoven, R. F., Engleman, E. G., & Mcguire, J. L. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780381216 · Cited by 192
Cited by
Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus
Roman, M. J., Shanker, B.-A., Davis, A., Lockshin, M. D., Sammaritano, L., Simantov, R., Crow, M. K., Schwartz, J. E., Paget, S. A., Devereux, R. B., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035471 · Cited by 1,427
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Self-citationManagement strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Self-citationAndrogen-Induced Immunosuppression
Gubbels Bupp, M. R., & Jorgensen, T. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00794 · Cited by 390
Reproductive and menopausal factors and risk of systemic lupus erythematosus in women
Costenbader, K. H., Feskanich, D., Stampfer, M. J., & Karlson, E. W. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22510 · Cited by 349
Dehydroepiandrosterone (DHEA): Hypes and Hopes
Rutkowski, K., Sowa, P., Rutkowska-Talipska, J., Kuryliszyn-Moskal, A., & Rutkowski, R. (2014) · Drugs · doi:10.1007/s40265-014-0259-8 · Cited by 216
Immunomodulators in SLE: Clinical evidence and immunologic actions
Durcan, L., & Petri, M. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.010 · Cited by 92
Self-citation
Metadata
- Authors
- Petri, M. A., Lahita, R. G., Van Vollenhoven, R. F., Merrill, J. T., Schiff, M., Ginzler, E. M., Strand, V., Kunz, A., Gorelick, K. J., & Schwartz, K. E.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2002-07
- Volume
- 46
- Issue
- 7
- Pages
- 1820-1829
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2079279434
- Cited by
- 159
- References
- 4
- FWCI
- 10.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.